Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis ...

Credit: Getty Images. In response to the letter, Intercept has ... NCT02548351), which enrolled patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.

Findings showed that 26% and 30% of patients treated with resmetirom 80mg and 100mg, respectively, achieved NASH resolution with at least a 2-point reduction in NAS and no worsening of fibrosis ...

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial A supportive analysis using consensus ...

Nonalcoholic steatohepatitis (NASH) is an aggressive form of fatty liver disease. Currently, there is no effective treatment, but new research shows that vitamin B12 and folate could help reduce ...

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial A supportive analysis using consensus ...

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus ...

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus ...